Azenta, Inc. Reports Solid Q2 2025 Revenue Growth

Azenta, Inc. ( (AZTA) ) has released its Q2 earnings. Here is a breakdown of the information Azenta, Inc. presented to its investors.

Azenta, Inc. is a leading provider of life sciences solutions, specializing in cold-chain sample management and multiomics services for pharmaceutical, biotech, academic, and healthcare institutions worldwide.

In its latest earnings report for the second quarter of fiscal 2025, Azenta, Inc. reported a revenue of $143 million, marking a 5% increase compared to the same period last year. The company continues to demonstrate resilience in its operations despite a challenging macroeconomic environment.

Key financial highlights include a 6% organic revenue growth year-over-year, with Sample Management Solutions and Multiomics segments contributing significantly. Sample Management Solutions revenue increased by 8%, driven by higher sales in consumables and instruments. Multiomics revenue rose by 2%, supported by growth in Next Generation Sequencing. The company also reported an adjusted EBITDA of $14 million, reflecting a 75% year-over-year increase.

Despite these positive trends, Azenta faced a diluted EPS loss from continuing operations of $0.40, compared to a loss of $0.29 in the previous year. The operating loss was $16 million, although the operating margin improved by 650 basis points year-over-year due to higher revenue and operational efficiencies.

Looking ahead, Azenta remains confident in its strategic positioning and plans to continue investing in long-term growth initiatives. The company maintains its revenue guidance for fiscal 2025, expecting organic revenue growth between 3% and 5% and an adjusted EBITDA margin expansion of approximately 300 basis points.